CCND1 and mantle cell lymphoma: Besides the currently approved indications, venetoclax demonstrated promising clinical activity in patients with mantle cell lymphoma (MCL), a lymphoma subtype molecularly characterized by the translocation t(11;14) leading to overexpression of cyclin D1 [76].